During the third quarter of 2007, Strattera generated $130.5 million of sales, a 3 percent increase compared with the third quarter of 2006. U.S. sales decreased 8 percent to $103.6 million, due to a decline in demand. Sales outside the U.S. increased 91 percent to $26.9 million, due primarily to higher demand.
Other Diabetes Care Products
As previously disclosed, Lilly's U.S. marketing rights with respect to Actos(R) expired in September 2006; however, Lilly will continue to receive royalties from Takeda Pharmaceuticals North America at a declining rate through September 2009. Lilly continues to market the product in many countries outside the U.S. In the third quarter, Actos generated $97.8 million of revenue for Lilly, over half of which was outside the U.S. Actos revenue increased 27 percent versus the third quarter of 2006.
Worldwide sales of Byetta were $164.8 million in the third quarter, a 30 percent increase compared with the third quarter of 2006. Lilly reports as revenue its 50 percent share of Byetta's gross margin in the U.S., 100 percent of Byetta sales outside the U.S., and its sales of Byetta pen delivery devices to its partner, Amylin Pharmaceuticals. For the third quarter, Lilly recognized revenue totaling $87.1 million, representing a 40 percent increase compared with the third quarter of 2006.
Worldwide sales of animal health products in the third quarter were
$236.6 million, an increase of 9 percent compared with the third quarter of
2006. U.S. sales grew 15 percent to $112.4 million while sales outside the
U.S. grew 5 percent to $124.2 million. Sales g
|SOURCE Eli Lilly and Company|
Copyright©2007 PR Newswire.
All rights reserved